R&D News | pharmaphorum

News

Cellectis rockets on gene-editing alliance with AstraZeneca

Shares in Cellectis shot up this morning after the French biotech revealed a wide-ranging alliance with AstraZeneca, which includes $245 million in near-term financial com

News

GSK licenses hepatitis B drug from J&J in $1bn deal

GSK has set its sights on dominance of the market for hepatitis B virus (HBV) therapeutics, licensing an antisense oligonucleotide drug from Arrowhead Pharma and Johnson &

News

Lilly buys Beam’s option on Verve drug programmes

Eli Lilly has agreed to buy a gene-editing programme for cardiovascular diseases from Beam Therapeutics in a deal, valued at up to $600 million, that ties in with the biot

News

Despite trial miss, Sarepta plans new filing for DMD therapy

Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy has failed to meet its primary objective in a phase 3 trial, but the company says it will file to extend

News

Atrasentan data backs up Novartis’ $3.5bn Chinook deal

Novartis’ bid to build a strong presence in the treatment of rare kidney disease IgA nephropathy (IgAN) has been boosted by phase 3 data with atrasentan, the main asset in

News

Merck signs €1.4bn cancer alliance with China’s Hengrui

Germany’s Merck KGaA has reached a deal with Chinese pharma company Jiangsu Hengrui that covers a pair of cancer drugs, including a ‘next-generation’ PARP inhibitor and an

Cellectis rockets on gene-editing alliance with AstraZeneca

GSK licenses hepatitis B drug from J&J in $1bn deal

Lilly buys Beam’s option on Verve drug programmes

Despite trial miss, Sarepta plans new filing for DMD therapy

Atrasentan data backs up Novartis’ $3.5bn Chinook deal

Merck signs €1.4bn cancer alliance with China’s Hengrui

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks